Window of opportunity

Journal of Rheumatology

Volumn 31, Issue 9, 2004, Pages 1677-1679

  Furst, Daniel E ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; CHLOROQUINE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; HUMAN; META ANALYSIS; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 4444348186     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Harris ED Jr, Budd RC, Firestein GS, et al. Kelly's textbook of rheumatology. Philadelphia: W.B. Saunders Co.; 2001.
2. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
3. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771-4.
4. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
5. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the Hydroxychloroquine in Early Rheumatoid Arthritis (HERA) study. J Rheumatol 2000;27:623-9.
6. Borg G, Allander E, Lund B, et al. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J Rheumatol 1988;15:1747-54.
7. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
8. Kanevskaya MZ, Chichassova NV. Treatment of early RA: influence on activity and x-ray progression in a long-term, prospective study [abstract]. EULAR 2003, Lisbon, Portugal. Internet. [cited June 16, 2004]. Available from www://http.eular.org
9. Van der Heijde A, Jacobs JWG, van der Veen MJ, et al. The effectiveness of early treatment with "second line" anti-rheumatic drugs, a randomized, controlled trial. Ann Intern Med 1996;124:699-707.
10. Verstappen S, Jacobs J, Bijlsma J, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying anti-rheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003; 48:1797-807.
11. Amjadi-Begvand S, Khanna D, Park GS, Bulpitt KJ, Wong WK, Paulus HE. Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. J Rheumatol 2004;31:1686-92.
12. Firestein G. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.